comparemela.com

Hagopm Kantarjian News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Redefining Research Practices in Search of a Cure

Advances in Ph+ ALL: Evolving Therapies and Future Strategies

Advances in Ph+ ALL: Evolving Therapies and Future Strategies
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

Optimizing Real-World Ponatinib Use in Ph+ ALL: Treatment Considerations

Early Cytogenetic or Molecular Landmark Response to Ponatinib Predicts Outcomes in CP-CML

Early cytogenetic and molecular responses achieved with ponatinib was significantly linked with better long-term progression-free survival and overall survival in patients with highly resistant, pretreated chronic-phase chronic myeloid leukemia.

Dr Kantarjian on the Predictive Value of Early Responses to Ponatinib in CP-CML

Hagop M. Kantarjian, MD, discusses the predictive value of early landmark cytogenetic or molecular responses to ponatinib in heavily pretreated patients with chronic-phase chronic myeloid leukemia.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.